Putting digitally empowered patients at the core of rare cancer research
Patient-centricity in pharma is of the moment, but in the rare disease space it has been a reality for many years
Search Results for: Professor Andy Hall
November 2021
As we move firmly into winter, the NHS continues to deliver COVID-19 booster jabs at pace....
Read More
Company focus: Exscientia
With several high-profile collaborations under its belt, Exscientia is bringing AI tech straight to the heart of pharma R&D. We asked the company’s founder, Professor Andrew Hopkins, to explain how they’re hoping to make long, expensive drug development a thing of the past
Read More
Oxford and AstraZeneca aim to produce Omicron-targeted version of vaccine
Calls for booster vaccinations in order to combat the rising cases brought about by winter and the recent Omicron variant have intensified, in the midst of record case rates.
Read More
The Pharma Fast 50
PharmaTimes presents Alantra’s annual ranking of the fastest growing private pharma companies in the UK
Read More- 1
- 2
- Cambridge researchers develop robotic nerve devices for neurological conditions
- International phase 3 clinical trial for new melanoma treatment recruits first patients
- Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
- Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
